In the first quarter of fiscal 2022, Genmab has received USD 19.5m from sales of multiple sclerosis drug Kesimpta, which has been licensed to Swiss firm Novartis.
Genmab is behind the active ingredient, ofatumumab, in Novartis’ Kesimpta, and the Danish biotech firm receives 10-percent royalties from Novartis’s sales.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
WS Audiology brings in head of EMEA region from Coloplast
The hearing aid manufacturer has appointed Coloplast’s now outgoing president for emerging markets as president for the EMEA region.
Dupixent could dominate pediatric eczema market for up to a decade, analysis finds
Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.
The Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive project
Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms.
FDA advisors support approval for Ferring's intestinal infection medicine
All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
Pharmacosmos expects massive growth in four years
The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.
Pharmacovigilance & Regulatory Assistant with an interest in non-fiction 
Process Supporter working with SAP 
Regulatory Project Manager 
CMC Writer 
Senior CMC Regulatory Manager 
KLIFO is looking for a Compliance Coordinator for our Glostrup office 
Manager of QA, BHS Logistics 
Nordic Key Account Manager, Hollister & Dansac 
Vice President, Medical Affairs 
Product specialist 
Ambitious Business Relationship Manager for the Danish Medicines Agency 
Chief Business Officer 
eTMF Manager 
Clinical Project Lead